Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| SOFIE Biosciences | GE HealthCare Technologies Inc. | In-Vivo Diagnostic & Testing Substances | $945M | 10× – 14× | |
| SOFIE Biosciences | GE HealthCare | In-Vivo Diagnostic & Testing Substances | $235M – $315M | 11× – 14× | |
| Redwave Medical GmbH | MedTec & Science Gruppe, custo med GmbH | In-Vivo Diagnostic & Testing Substances | $10.7M – $14.5M | 7× – 9× | |
| Lantheus Holdings, Inc. | Curium US Holdings | In-Vivo Diagnostic & Testing Substances | $8,000M | 14× – 18× | |
| Lantheus Holdings, Inc. | Curium, CapVest Partners LLP | In-Vivo Diagnostic & Testing Substances | $8,000M | 15× – 19× | |
| BWXT Medical | Nordic Capital | In-Vivo Diagnostic & Testing Substances | $800M | 11× – 14× | |
| BWX Technologies Medical business, Kinectrics stable medical isotopes business | Nordic Capital | In-Vivo Diagnostic & Testing Substances | $800M | 14× – 18× | |
| Lantheus Holdings, Inc. | Curium | In-Vivo Diagnostic & Testing Substances | $8,000M | 9× – 12× | |
| Accellix | bioMérieux | In-Vivo Diagnostic & Testing Substances | $160M – $190M | 12× – 14× | |
| Navidea Biopharmaceuticals, Inc. | Cardinal Health, Inc. | In-Vivo Diagnostic & Testing Substances | $18.0M – $21.6M | 6× – 7× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.